Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.91
-0.36 (-0.17%)
AAPL  272.12
+5.94 (2.23%)
AMD  209.03
+12.43 (6.32%)
BAC  50.53
-0.54 (-1.06%)
GOOG  308.08
-3.61 (-1.16%)
META  634.01
-3.24 (-0.51%)
MSFT  386.58
+2.11 (0.55%)
NVDA  189.26
-2.29 (-1.19%)
ORCL  143.32
+2.01 (1.42%)
TSLA  402.38
+2.55 (0.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.